{"disease":{"id":"appetite-loss-cachexia","name":"Appetite loss / Cachexia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-07258669","indication_name":"Appetite loss / Cachexia","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07258669","generic_name":"pf-07258669","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Melanocortin-4 receptor (MC4R)","drug_class":"MC4R antagonist","quality_score":null,"revenue":null,"mechanism":"PF-07258669 is a selective MC4R antagonist that blocks melanocortin-4 receptor signaling to increase appetite and food intake."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}